List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1142888/publications.pdf Version: 2024-02-01

	7551	10708
21,584	77	138
citations	h-index	g-index
257	257	18320
docs citations	times ranked	citing authors
	21,584 citations 257 docs citations	21,584 citations 257 docs citations 77 h-index 257 257 times ranked

#	Article	IF	CITATIONS
1	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genetics, 2013, 45, 164-171.	9.4	843
2	Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States. Gastroenterology, 2008, 135, 1924-1934.e4.	0.6	748
3	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology, 2015, 148, 1340-1352.e7.	0.6	646
4	ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. American Journal of Gastroenterology, 2014, 109, 950-966.	0.2	631
5	Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology, 2009, 136, 138-148.	0.6	570
6	Des-Î ³ -Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Gastroenterology, 2010, 138, 493-502.	0.6	524
7	Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Annals of Internal Medicine, 2005, 142, 439.	2.0	485
8	Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine, 2008, 359, 2429-2441.	13.9	445
9	Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3â~†. Gastroenterology, 2004, 126, 1015-1023.	0.6	436
10	Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 2010, 52, 833-844.	3.6	428
11	Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate. Circulation Research, 2008, 102, 669-676.	2.0	420
12	Drug-Induced Liver Injury Network (DILIN) Prospective Study. Drug Safety, 2009, 32, 55-68.	1.4	416
13	Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial. Clinical Gastroenterology and Hepatology, 2010, 8, 877-883.	2.4	385
14	Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 1999, 29, 264-270.	3.6	377
15	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. New England Journal of Medicine, 2020, 382, 2289-2301.	13.9	350
16	Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology, 2014, 60, 1399-1408.	3.6	326
17	Hepatic histological findings in suspected drugâ€induced liver injury: Systematic evaluation and clinical associations. Hepatology, 2014, 59, 661-670.	3.6	322
18	Heme Oxygenase: Recent Advances in Understanding Its Regulation and Role. Proceedings of the Association of American Physicians, 1999, 111, 438-447.	2.1	281

#	Article	IF	CITATIONS
19	Porphyria. New England Journal of Medicine, 2017, 377, 862-872.	13.9	272
20	Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america. Hepatology, 1998, 27, 1661-1669.	3.6	252
21	Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine, 2015, 373, 48-59.	13.9	206
22	Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology, 2007, 132, 103-112.	0.6	200
23	Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology, 2014, 60, 679-686.	3.6	200
24	Hepatotoxicity Associated with Supplements Containing Chinese Green Tea (<i>Camellia sinensis</i>). Annals of Internal Medicine, 2006, 144, 68.	2.0	199
25	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine, 2019, 380, 549-558.	13.9	194
26	Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. American Journal of Gastroenterology, 2000, 95, 272-276.	0.2	190
27	Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases. Clinical Gastroenterology and Hepatology, 2013, 11, 558-564.e3.	2.4	187
28	Acute Porphyrias in the USA: Features of 108ÂSubjects from Porphyrias Consortium. American Journal of Medicine, 2014, 127, 1233-1241.	0.6	185
29	Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C. Gastroenterology, 2011, 140, 840-849.e1.	0.6	178
30	Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology, 2012, 56, 300-310.	3.6	177
31	MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology, 2010, 51, 1494-1504.	3.6	176
32	Candidate biomarkers for the diagnosis and prognosis of drugâ€induced liver injury: An international collaborative effort. Hepatology, 2019, 69, 760-773.	3.6	166
33	Recent insights into the biological functions of liver fatty acid binding protein 1. Journal of Lipid Research, 2015, 56, 2238-2247.	2.0	164
34	lron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology, 2000, 32, 135-138.	3.6	162
35	Reciprocal Effects of Micro-RNA-122 on Expression of Heme Oxygenase-1 and Hepatitis C Virus Genes in Human Hepatocytes. Gastroenterology, 2007, 133, 1166-1174.	0.6	157
36	Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology, 2008, 47, 789-798.	3.6	155

#	Article	IF	CITATIONS
37	Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2010, 51, 585-594.	3.6	155
38	Iron reduction before and during interferon therapy of chronic hepatitisÂC: Results of a multicenter, randomized, controlled trial. Hepatology, 2000, 31, 730-736.	3.6	154
39	Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology, 2009, 50, 1360-1369.	3.6	153
40	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology, 2006, 44, 1675-1684.	3.6	145
41	Hepatic Iron Concentration: Noninvasive Estimation by Means of MR Imaging Techniques. Radiology, 1999, 212, 227-234.	3.6	144
42	Role of Bach1 and Nrf2 in upâ€regulation of the heme oxygenaseâ€1 gene by cobalt protoporphyrin. FASEB Journal, 2006, 20, 2651-2653.	0.2	142
43	A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology, 2011, 54, 396-405.	3.6	142
44	Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transplantation, 2005, 11, 1590-1596.	1.3	136
45	Porphyrin and Heme Metabolism and the Porphyrias. , 2013, 3, 365-401.		134
46	Drug-Induced Liver Injury Associated with Statins. Seminars in Liver Disease, 2009, 29, 412-422.	1.8	132
47	lron as a comorbid factor in chronic viral hepatitis. American Journal of Gastroenterology, 2002, 97, 1-4.	0.2	129
48	Autoimmune Hepatitis Triggered by Statins. Journal of Clinical Gastroenterology, 2006, 40, 757-761.	1.1	128
49	Nutritional supplementation in chronic liver disease: An analytical review. Hepatology, 1994, 19, 518-533.	3.6	127
50	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Journal of Hepatology, 2007, 46, 420-431.	1.8	125
51	Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Gastroenterology, 2009, 137, 549-557.	0.6	125
52	Prevalence and prediction of osteopenia in chronic liver disease. Hepatology, 1990, 12, 273-280.	3.6	123
53	Acute hepatic porphyrias: Recommendations for evaluation and longâ€ŧerm management. Hepatology, 2017, 66, 1314-1322.	3.6	122
54	Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology, 1987, 7, 423-429.	3.6	116

#	Article	IF	CITATIONS
55	Iron in Nonhemochromatotic Liver Disorders. Seminars in Liver Disease, 2005, 25, 461-472.	1.8	116
56	Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology, 2008, 47, 605-612.	3.6	114
57	Lon Peptidase 1 (LONP1)-dependent Breakdown of Mitochondrial 5-Aminolevulinic Acid Synthase Protein by Heme in Human Liver Cells. Journal of Biological Chemistry, 2011, 286, 26424-26430.	1.6	111
58	Drug-Induced Liver Injury with Autoimmune Features. Seminars in Liver Disease, 2014, 34, 194-204.	1.8	109
59	Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. Journal of Hepatology, 2002, 37, 848-854.	1.8	108
60	United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicology Reports, 2020, 7, 386-402.	1.6	108
61	Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology, 1999, 29, 1672-1679.	3.6	107
62	Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology, 2017, 65, 1267-1277.	3.6	105
63	Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. Gastroenterology, 1990, 99, 1079-1091.	0.6	104
64	A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology, 2010, 52, 1671-1779.	3.6	103
65	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology, 2020, 71, 1546-1558.	3.6	103
66	Induction of the Heme Oxygenase-1 Gene by Metalloporphyrins. Archives of Biochemistry and Biophysics, 2000, 380, 219-227.	1.4	100
67	Herbal Products and the Liver: A Review of Adverse Effects andÂMechanisms. Gastroenterology, 2015, 148, 517-532.e3.	0.6	97
68	Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: An analytical review. Hepatology, 2010, 51, 690-698.	3.6	96
69	Hepatitis <scp>C</scp> , porphyria cutanea tarda and liver iron: an update. Liver International, 2012, 32, 880-893.	1.9	96
70	Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol, 2003, 30, 137-144.	0.8	93
71	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut, 2010, 59, 1401-1409.	6.1	92
72	Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias. Metabolites, 2014, 4, 977-1006.	1.3	92

#	Article	IF	CITATIONS
73	Amoxicillin–Clavulanate-Induced Liver Injury. Digestive Diseases and Sciences, 2016, 61, 2406-2416.	1.1	92
74	Acute Hepatic Porphyrias: Review and Recent Progress. Hepatology Communications, 2019, 3, 193-206.	2.0	91
75	The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 1113-1122.	0.9	89
76	Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. Gastroenterology, 2006, 131, 1440-1451.	0.6	83
77	Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. Gastroenterology, 2010, 138, 136-146.	0.6	82
78	microRNAs: Fad or future of liver disease. World Journal of Gastroenterology, 2011, 17, 2536.	1.4	80
79	Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2009, 49, 1847-1858.	3.6	75
80	Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World Journal of Gastroenterology, 2016, 22, 6742.	1.4	74
81	Hepatic microsomal function in rats with chronic dietary iron overload. Gastroenterology, 1986, 90, 1844-1853.	0.6	72
82	Interleukin-8 and hIRH (SDF1-?/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. Hepatology, 1998, 28, 108-115.	3.6	72
83	Catechins in Dietary Supplements and Hepatotoxicity. Digestive Diseases and Sciences, 2013, 58, 2682-2690.	1.1	71
84	Profiles of Serum Cytokines in Acute Drug-Induced Liver Injury and Their Prognostic Significance. PLoS ONE, 2013, 8, e81974.	1.1	71
85	Choline may be an essential nutrient in malnourished patients with cirrhosis. Gastroenterology, 1989, 97, 1514-1520.	0.6	70
86	Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria. JAMA Dermatology, 2017, 153, 789.	2.0	70
87	High-performance liquid chromatographic separation and quantitation of tetrapyrroles from biological materials. Analytical Biochemistry, 1986, 155, 56-64.	1.1	68
88	Iron Levels in Hepatocytes and Portal Tract Cells Predict Progression and Outcomes of Patients With Advanced Chronic Hepatitis C. Gastroenterology, 2011, 140, 1490-1500.e3.	0.6	64
89	Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). Molecular Genetics and Metabolism, 2019, 128, 213-218.	0.5	63
90	Fatal liver failure in protoporphyria. Gastroenterology, 1986, 90, 191-201.	0.6	62

#	Article	IF	CITATIONS
91	Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Digestive Diseases and Sciences, 2002, 47, 1632-1637.	1.1	62
92	Role of Bach-1 in Regulation of Heme Oxygenase-1 in Human Liver Cells. Journal of Biological Chemistry, 2004, 279, 51769-51774.	1.6	62
93	The Neuromediator Glutamate, through Specific Substrate Interactions, Enhances Mitochondrial ATP Production and Reactive Oxygen Species Generation in Nonsynaptic Brain Mitochondria. Journal of Biological Chemistry, 2009, 284, 14448-14456.	1.6	62
94	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. Journal of Hepatology, 2015, 63, 1103-1110.	1.8	61
95	Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. Hepatology, 2009, 50, 1738-1749.	3.6	60
96	Biochemistry and Pharmacology of S-Adenosyl-L-Methionine and Rationale for its Use in Liver Disease. Drugs, 1990, 40, 98-110.	4.9	59
97	Phlebotomy Improves Therapeutic Response to Interferon in Patients with Chronic Hepatitis C: A Meta-Analysis of Six Prospective Randomized Controlled Trials. Digestive Diseases and Sciences, 2008, 53, 815-822.	1.1	58
98	BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signalingÂinÂhepatocellular carcinoma. Cancer Letters, 2017, 411, 117-129.	3.2	58
99	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology, 2011, 53, 1100-1108.	3.6	55
100	Hepatotoxicity Associated with the Use of Anti-TNF-Î \pm Agents. Drug Safety, 2016, 39, 199-208.	1.4	54
101	Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): A growing concern. Journal of Hepatology, 2006, 45, 334-335.	1.8	52
102	Metabolic and functional differences between brain and spinal cord mitochondria underlie different predisposition to pathology. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R844-R854.	0.9	52
103	Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology, 2009, 49, 1828-1837.	3.6	51
104	Hereditary Hemochromatosis: Time for Targeted Screening. Annals of Internal Medicine, 2008, 149, 270.	2.0	50
105	Purification and characterization of heme oxygenase from chick liver. Comparison of the avian and mammalian enzymes. FEBS Journal, 1990, 189, 155-166.	0.2	49
106	Profiles of mi <scp>RNA</scp> s in serum in severe acute drug induced liver injury and their prognostic significance. Liver International, 2017, 37, 757-764.	1.9	49
107	BENEFITS OF CHRONIC PLASMAPHERESIS AND INTRAVENOUS HEME-ALBUMIN IN ERYTHROPOIETIC PROTOPORPHYRIA AFTER ORTHOTOPIC LIVER TRANSPLANTATION 12. Transplantation, 2002, 73, 469-472.	0.5	48
108	Acute Porphyrias. Journal of Emergency Medicine, 2015, 49, 305-312.	0.3	47

7

#	Article	IF	CITATIONS
109	Molecular basis for heme-dependent induction of heme oxygenase in primary cultures of chick embryo hepatocytes. Demonstration of acquired refractoriness to heme. FEBS Journal, 1993, 213, 909-917.	0.2	46
110	HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. Journal of Hepatology, 2006, 45, 5-12.	1.8	46
111	HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology, 2006, 44, 360-367.	3.6	46
112	Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology, 2007, 5, 245-254.	2.4	46
113	Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells. Hepatology, 1989, 10, 354-364.	3.6	44
114	Ubiquitin as a Marker of Cell Injury in Nonalcoholic Steatohepatitis. American Journal of Clinical Pathology, 2000, 114, 860-866.	0.4	44
115	Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. British Journal of Pharmacology, 2003, 139, 634-640.	2.7	44
116	miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS ONE, 2018, 13, e0200847.	1.1	44
117	Porphyrin-Induced Protein Oxidation and Aggregation as a Mechanism of Porphyria-Associated Cell Injury. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 535-548.	2.3	44
118	Advances in understanding and treating â€~the little imitator,' acute porphyria. Gastroenterology, 1993, 105, 590-594.	0.6	43
119	DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology, 2008, 49, 548-556.	1.8	43
120	Novel role of nuclear receptor rev-erbα in hepatic stellate cell activation: Potential therapeutic target for liver injury. Hepatology, 2014, 59, 2383-2396.	3.6	43
121	Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Alimentary Pharmacology and Therapeutics, 2019, 49, 1195-1204.	1.9	43
122	Genetic Aspects of Porphyria Cutanea Tarda. Seminars in Liver Disease, 2007, 27, 099-108.	1.8	42
123	Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2009, 7, 219-226.	2.4	42
124	THE VALUE OF INTRAVENOUS HEME-ALBUMIN AND PLASMAPHERESIS IN REDUCING POSTOPERATIVE COMPLICATIONS OF ORTHOTOPIC LIVER TRANSPLANTATION FOR ERYTHROPOIETIC PROTOPORPHYRIA1,2. Transplantation, 1999, 67, 922-928.	0.5	42
125	Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration. American Journal of Gastroenterology, 2008, 103, 2757-2765.	0.2	41
126	Efficacy and safety of givosiran for acute hepatic porphyria: 24â€month interim analysis of the randomized phase 3 ENVISION study. Liver International, 2022, 42, 161-172.	1.9	41

#	Article	IF	CITATIONS
127	Fatal air and bile embolism after percutaneous liver biopsy and ERCP. Gastrointestinal Endoscopy, 2005, 61, 153-157.	0.5	38
128	Heme catabolism in cultured hepatocytes: evidence that heme oxygenase is the predominant pathway and that a proportion of synthesized heme is converted rapidly to biliverdin. Biochimica Et Biophysica Acta - General Subjects, 1989, 992, 49-58.	1.1	37
129	Reconstitution of Hematin for Intravenous Infusion. Annals of Internal Medicine, 2006, 144, 537.	2.0	37
130	Case 20-2008. New England Journal of Medicine, 2008, 358, 2813-2825.	13.9	37
131	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514.	3.0	37
132	Subcellular Tissue Proteomics of Hepatocellular Carcinoma for Molecular Signature Discovery. Journal of Proteome Research, 2011, 10, 5070-5083.	1.8	36
133	BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial–mesenchymal transition via upregulating ID2. Cancer Letters, 2017, 390, 67-76.	3.2	36
134	Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World Journal of Gastroenterology, 2009, 15, 4499.	1.4	36
135	The porphyrias. Disease-a-Month, 1989, 35, 7-54.	0.4	35
136	Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. World Journal of Gastroenterology, 2013, 19, 7836.	1.4	34
137	Repression of hepatic δ-aminolevulinate synthase by heme and metalloporphyrins: Relationship to inhibition of heme oxygenase. Hepatology, 1993, 18, 119-127.	3.6	33
138	Iron and Chronic Viral Hepatitis: Emerging Evidence for an Important Interaction. Digestive Diseases, 1995, 13, 223-238.	0.8	33
139	IFN-alpha Receptor mRNA Expression in a United States Sample with Predominantly Genotype 1a/I Chronic Hepatitis C Liver Biopsies Correlates with Response to IFN Therapy. Journal of Interferon and Cytokine Research, 1999, 19, 1011-1018.	0.5	33
140	Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Molecular and Cellular Biochemistry, 2008, 319, 153-161.	1.4	33
141	Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochemical Journal, 2005, 392, 173-180.	1.7	32
142	Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology, 2005, 41, 617-625.	3.6	32
143	Zinc Mesoporphyrin Induces Rapid Proteasomal Degradation of Hepatitis C Nonstructural 5A Protein in Human Hepatoma Cells. Gastroenterology, 2010, 138, 1909-1919.e3.	0.6	32
144	Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. Journal of Immunotoxicology, 2017, 14, 31-38.	0.9	32

#	Article	IF	CITATIONS
145	Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology, 2021, 73, 1736-1746.	3.6	32
146	Hepatic heme synthesis in a new model of experimental hemochromatosis: Studies in rats fed finely divided elemental iron. Hepatology, 1987, 7, 1195-1203.	3.6	31
147	Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology, 2009, 137, 1986-1994.	0.6	31
148	Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. Liver International, 2010, 30, 1490-1504.	1.9	31
149	Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2†T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine, 2019, 44, 209-224.	2.7	31
150	Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction. Molecular Genetics and Metabolism, 2019, 128, 242-253.	0.5	31
151	Respiration and ROS production in brain and spinal cord mitochondria of transgenic rats with mutant G93a Cu/Zn-superoxide dismutase gene. Neurobiology of Disease, 2011, 44, 53-62.	2.1	30
152	Mapping of the Chick Heme Oxygenase-1 Proximal Promoter for Responsiveness to Metalloporphyrins. Archives of Biochemistry and Biophysics, 2002, 399, 159-166.	1.4	29
153	Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrias. Clinical Chemistry, 2015, 61, 1453-1456.	1.5	29
154	Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. PLoS ONE, 2018, 13, e0206389.	1.1	29
155	Effects of silymarin on hepatitis C virus and haem oxygenaseâ€1 gene expression in human hepatoma cells. Liver International, 2009, 29, 366-373.	1.9	28
156	Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. Journal of Proteomics, 2011, 74, 79-88.	1.2	28
157	Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2008, 6, 234-241.	2.4	26
158	Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity. Digestive Diseases and Sciences, 2013, 58, 1766-1775.	1.1	26
159	miRâ€122 decreases HCV entry into hepatocytes through binding to the 3′ UTR of OCLN <scp>mRNA</scp> . Liver International, 2015, 35, 1315-1323.	1.9	26
160	Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. Hepatology Research, 2007, 37, 172-178.	1.8	25
161	Chronic Hepatitis E with Neurologic Manifestations and Rapid Progression of Liver Fibrosis in a Liver Transplant Recipient. Digestive Diseases and Sciences, 2013, 58, 2413-2416.	1.1	25
162	An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. PLoS ONE, 2011, 6, e20904.	1.1	25

HERBERT L BONKOVSKY

#	Article	IF	CITATIONS
163	Regulation of expression of the human heme oxygenase-1 gene in transfected chick embryo liver cell cultures. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1352, 293-302.	2.4	24
164	CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. Journal of Clinical Virology, 2009, 46, 259-264.	1.6	24
165	Benefits of prophylactic heme therapy in severe acute intermittent porphyria. Molecular Genetics and Metabolism Reports, 2019, 19, 100450.	0.4	24
166	Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians. American Journal of the Medical Sciences, 2021, 362, 113-121.	0.4	24
167	Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation‖‖Abbreviations: ACE, angiotensin converting enzyme; ALA, 5-aminolevulinate; CELCs, chick embryo liver cells; and DES, desferrioxamine Biochemical Pharmacology, 1999, 58, 887-896.	2.0	23
168	Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor bach1 and up-regulates HO-1. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2008, 1779, 195-203.	0.9	23
169	Advances in the management of erythropoietic protoporphyria – role of afamelanotide. The Application of Clinical Genetics, 2016, Volume 9, 179-189.	1.4	23
170	Effects of mifepristone (RU-486) on heme metabolism and cytochromes P -450 in cultured chick embryo liver cells. Possible implications for acute porphyria. FEBS Journal, 1994, 225, 651-657.	0.2	22
171	Enhanced Phenotypic Expression of Alpha-1-Antitrypsin Deficiency in an MZ Heterozygote With Chronic Hepatitis C. American Journal of Gastroenterology, 1998, 93, 1541-1545.	0.2	22
172	Mallory–Denk Bodies Are Associated With Outcomes and Histologic Features in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2011, 9, 902-909.e1.	2.4	22
173	Synergistic induction of δ-aminolevulinate synthase by glutethimide and iron: relationship to the synergistic induction of heme oxygenase. BBA - Proteins and Proteomics, 1991, 1080, 245-251.	2.1	21
174	Urea and hypertonicity increase expression of heme oxygenase-1 in murine renal medullary cells. American Journal of Physiology - Renal Physiology, 2001, 281, F983-F991.	1.3	21
175	<scp>YKL</scp> â€40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver International, 2012, 32, 665-674.	1.9	21
176	Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology, 2009, 50, 1719-1726.	3.6	20
177	Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias. Molecular Genetics and Metabolism, 2019, 128, 228-235.	0.5	20
178	Effects of Phenylarsine Oxide on Expression of Heme Oxygenase-1 Reporter Constructs in Transiently Transfected Cultures of Chick Embryo Liver Cells. Archives of Biochemistry and Biophysics, 1999, 372, 224-229.	1.4	19
179	Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World Journal of Gastroenterology, 2014, 20, 14142.	1.4	19
180	Identification of key elements that are responsible for heme-mediated induction of the avian heme oxygenase-1 gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1679, 87-94.	2.4	18

HERBERT L BONKOVSKY

#	Article	IF	CITATIONS
181	Homeostasis of iron and hepcidin in erythropoietic protoporphyria. European Journal of Clinical Investigation, 2015, 45, 1032-1041.	1.7	18
182	Associations of gender and a proxy of female menopausal status with histological features of drugâ€induced liver injury. Liver International, 2017, 37, 1723-1730.	1.9	18
183	Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World Journal of Gastroenterology, 2011, 17, 1694.	1.4	18
184	Hepatic 5-Aminolevulinic Acid Synthase mRNA Stability is Modulated by Inhibitors of Heme Biosynthesis and by Metalloporphyrins. FEBS Journal, 1996, 240, 112-117.	0.2	17
185	Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. Clinica Chimica Acta, 2011, 412, 2241-2247.	0.5	17
186	Chinese medicine for treatment of chronic hepatitis B. Chinese Journal of Integrative Medicine, 2012, 18, 253-255.	0.7	17
187	Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria. Genetics in Medicine, 2021, 23, 140-148.	1.1	17
188	Effects of hemopexin on heme-mediated repression of 5-aminolevulinate synthase and induction of heme oxygenase in cultured hepatocytes. Hepatology, 1994, 20, 741-746.	3.6	16
189	Heme biosynthesis in a chicken hepatoma cell line (LMH): comparison with primary chick embryo liver cells (CELC). Biochimica Et Biophysica Acta - General Subjects, 1999, 1472, 658-667.	1.1	16
190	Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2011, 106, 884-893.	0.2	16
191	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. Genetics in Medicine, 2019, 21, 2605-2613.	1.1	16
192	Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria. Molecular Genetics and Metabolism, 2019, 128, 376-381.	0.5	16
193	Porphyric neuropathy. Muscle and Nerve, 2021, 64, 140-152.	1.0	16
194	Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes. PLoS ONE, 2011, 6, e20922.	1.1	16
195	Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. Journal of Hepatology, 2022, 76, 832-840.	1.8	16
196	Colonic mucosal appearance of Tangier disease in a new patient. Gastrointestinal Endoscopy, 1994, 40, 628-630.	0.5	15
197	Management of recurrent hepatitis C after liver transplantation: a concise review. American Journal of Gastroenterology, 2000, 95, 2164-2170.	0.2	15
198	Marked Hyperbilirubinemia Associated With the Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism in a Boy With Autoimmune Hemolytic Anemia. Pediatrics, 2007, 119, e764-e767.	1.0	15

#	Article	IF	CITATIONS
199	DNA methylation patterns in alcoholics and family controls. World Journal of Gastrointestinal Oncology, 2012, 4, 138.	0.8	15
200	Herbal Dietary Supplement Associated Hepatotoxicity: AnÂUpcoming Workshop and Need for Research. Gastroenterology, 2015, 148, 480-482.	0.6	14
201	Porphyria. New England Journal of Medicine, 2017, 377, 2100-2101.	13.9	13
202	Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury. Clinical Gastroenterology and Hepatology, 2022, 20, e1416-e1425.	2.4	13
203	Genetic variations in heme oxygenase-1 and chronic hepatitis. Hepatology, 2010, 52, 400-401.	3.6	12
204	Givosiran, a novel treatment for acute hepatic porphyrias. Expert Review of Precision Medicine and Drug Development, 2021, 6, 9-18.	0.4	12
205	Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Drug Design, Development and Therapy, 0, Volume 16, 1827-1845.	2.0	12
206	Neonatal Androgenization Exacerbates Alcohol-Induced Liver Injury in Adult Rats, an Effect Abrogated by Estrogen. PLoS ONE, 2011, 6, e29463.	1.1	10
207	Circadian rhythms in acute intermittent porphyria – a pilot study. European Journal of Clinical Investigation, 2013, 43, 727-739.	1.7	10
208	No Role of the â^2518 Promoter Polymorphism of Monocyte Chemotactic Protein-1 in Chronic Hepatitis C. Gastroenterology, 2005, 129, 1361-1362.	0.6	9
209	Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis. Virology Journal, 2005, 2, 41.	1.4	9
210	Indications for liver transplant and AASLD guidelines. Hepatology, 2015, 61, 408-408.	3.6	8
211	Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria. Genetics in Medicine, 2020, 22, 590-597.	1.1	8
212	Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). Journal of Medical Economics, 2020, 23, 1441-1449.	1.0	8
213	Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist. Blood, 2020, 136, 51-51.	0.6	8
214	Porphyrin Loading of Lipofuscin Granules in Inflamed Striated Muscle. American Journal of Pathology, 1998, 153, 703-708.	1.9	7
215	Tissueâ€specific expression of ALA synthaseâ€1 and heme oxygenaseâ€1 and their expression in livers of rats chronically exposed to ethanol. FEBS Letters, 2008, 582, 1829-1834.	1.3	7
216	Drug-Induced Liver Injury. , 2012, , 417-461.		7

Drug-Induced Liver Injury. , 2012, , 417-461. 216

HERBERT L BONKOVSKY

#	Article	IF	CITATIONS
217	Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy. American Journal of Cardiology, 2015, 116, 1752-1755.	0.7	7
218	Risk factors for severe or fatal drugâ€induced liver injury from amoxicillin–clavulanic acid. Hepatology Research, 2015, 45, 676-682.	1.8	7
219	Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drugâ€Induced Liver Injury. Hepatology Communications, 2019, 3, 1032-1035.	2.0	7
220	A Low Iron Diet Protects from Steatohepatitis in a Mouse Model. Nutrients, 2019, 11, 2172.	1.7	7
221	Acute Hepatic Porphyrias: "Purple Flagsâ€â€"Clinical Features That Should Prompt Specific Diagnostic Testing. American Journal of the Medical Sciences, 2022, 363, 1-10.	0.4	7
222	<scp>Leflunomideâ€induced</scp> liver injury: Differences in characteristics and outcomes in Indian and <scp>US</scp> registries. Liver International, 2022, 42, 1323-1329.	1.9	7
223	Iron and Hepatitis C. Current Hepatitis Reports, 2010, 9, 169-177.	0.3	6
224	Leukocyte expression of heme oxygenase-1 [hmox1] varies inversely with severity of tricuspid regurgitation in acute pulmonary embolism. Thrombosis Research, 2015, 136, 769-774.	0.8	6
225	Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. Proteomics, 2013, 13, 3554-3562.	1.3	5
226	Hepatotoxicity of Anti-TNF Agents. Digestive Diseases and Sciences, 2014, 59, 1070-1071.	1.1	5
227	On Stress and the Liver: A Chicken and Egg Conundrum. Gastroenterology, 2015, 148, 894-897.	0.6	5
228	Acetaminophen Hepatotoxicity, Fasting, and Ethanol. JAMA - Journal of the American Medical Association, 1995, 274, 301.	3.8	4
229	Peripheral Neuropathy and the Ceruloplasmin Gene. Annals of Internal Medicine, 2018, 168, 894.	2.0	4
230	Heme status affects human hepatic messenger RNA and microRNA expression. World Journal of Gastroenterology, 2013, 19, 1593.	1.4	4
231	Assessment of porphyrogenicity of drugs and chemicals in selected hepatic cell culture models through a fluorescenceâ€based screening assay. Pharmacology Research and Perspectives, 2022, 10, e00951.	1.1	4
232	Design of the halt-C trial (Hepatitis C antiviral long-term treatment to prevent Cirrhosis). Gastroenterology, 2000, 118, A1435.	0.6	3
233	Cytoskeletal Proteins. International Review of Cell and Molecular Biology, 2013, 302, 279-319.	1.6	3
234	The Role of Traditional Chinese Medicines (TCM) and Other Complementary and Alternative Medicines (CAM) in the Management of Chronic Hepatitis B. Current Hepatology Reports, 2019, 18, 316-321.	0.4	3

#	Article	IF	CITATIONS
235	Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: Evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology, 1994, 19, 1141-1148.	3.6	3
236	Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. Blood, 2016, 128, 2318-2318.	0.6	3
237	Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database. Blood Advances, 2021, 5, 12-15.	2.5	3
238	Decreased Hepatic 5-Aminolevulinate Dehydrase in Experimental Hemochromatosis. Annals of the New York Academy of Sciences, 1988, 526, 365-368.	1.8	2
239	Structural analysis of heme proteins: Implication for design and prediction. , 2010, , .		2
240	Activation of the hepatocarcinogen aflatoxin B1 by forms of human hepatic cytochromes P-450: Some do and some don't. Hepatology, 1991, 13, 1003-1005.	3.6	1
241	Putting the freeze on hepatitis C virus-associated mixed cryoglobulinemia. Hepatology, 1995, 21, 594-597.	3.6	1
242	Iron, the major HFE gene mutation and chronic hepatitis C. Gastroenterology, 2000, 118, A953.	0.6	1
243	Regarding "Cobalt protoporphyrin as a potential therapeutic agent?― FASEB Journal, 2007, 21, 2640-2640.	0.2	1
244	Porphyria Cutanea Tarda: Profile of 189 Patients from the Porphyrias Consortium in the United States. Gastroenterology, 2017, 152, S1156.	0.6	1
245	Baseline Hepatic Levels of miR-29b and Claudin are Respectively Associated with the Stage of Fibrosis and HCV RNA in Hepatitis C. , 2019, 1, .		1
246	Relationship between nonalcoholic steatohepatitis and heterozygosity for the LCHAD (G1528C) mutation. Gastroenterology, 2003, 124, A748.	0.6	0
247	Intrahepatic Stainable Iron and Cardiac Dysfunction Pre- and Post- Orthotopic Liver Transplantation. Gastroenterology, 2011, 140, S-965.	0.6	0
248	Risk factors for porphyria cutanea tarda –the iron/ <scp>HFE</scp> connection. Liver International, 2013, 33, 162-162.	1.9	0
249	Reply. Hepatology, 2018, 67, 803-804.	3.6	0
250	Editorial: hepatitis C and porphyria cutanea tarda in 2020. Alimentary Pharmacology and Therapeutics, 2020, 51, 1432-1434.	1.9	0
251	Optimal Management of Nonalcoholic Fatty Liver/Steatohepatitis. Journal of Clinical Gastroenterology, 2003, 36, 193-195.	1.1	0